Related Experiment Video
Updated: Jan 13, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
DisCONtinuing aspirin for Cardiac Allograft Vasculopathy prophylaxis in heart transplant patients on concurrEnt
Alicia Bill1, Bruce E Blaine2, Anuradha Godishala3
1Department of Pharmacy, University of Rochester Medical Center, Rochester, NY, USA.
Insights
In heart transplant patients needing anticoagulation, adding aspirin did not increase major bleeding risk. Combined anticoagulation and aspirin (AC+ASA) was associated with lower mortality compared to anticoagulation alone (AC).
Area of Science:
- Cardiology
- Transplantation immunology
- Pharmacology
Background:
- Early aspirin use post-orthotopic heart transplant (OHT) may delay cardiac allograft vasculopathy (CAV).
- Limited guidance exists on continuing aspirin for CAV prophylaxis during therapeutic anticoagulation.
Purpose of the Study:
- To compare the safety and efficacy of anticoagulation alone (AC) versus combined anticoagulation and aspirin (AC+ASA) in OHT patients requiring therapeutic anticoagulation.
Main Methods:
- Single-center, retrospective, observational cohort study of adult OHT recipients.
- Primary outcome: major bleeding within the first month of anticoagulation.
- Secondary outcomes: bleeding events, CAV incidence, and mortality.
Main Results:
- No significant difference in major bleeding within one month between AC and AC+ASA groups (5 vs. 19 events, p=0.649).
- The AC group had significantly higher odds of death compared to the AC+ASA group (OR 0.07, 95% CI 0.01-0.32).
- No differences observed in other secondary outcomes.
Conclusions:
- In this cohort, combining anticoagulation with aspirin did not increase early major bleeding risk.
- Further research is needed on optimal anticoagulation strategies in the high-risk acute post-transplant period.
Background:
Early aspirin initiation after orthotopic heart transplant (OHT) has been associated with delayed progression of cardiac allograft vasculopathy (CAV). There is limited guidance on whether aspirin for CAV prophylaxis should be continued in the setting of therapeutic anticoagulation.
Objectives:
The purpose of this study is to compare the safety and efficacy of two antithrombotic strategies, anticoagulation alone (AC) versus combined anticoagulation and aspirin (AC+ASA), for patients with indications for therapeutic anticoagulation.
Methods:
This was a single-center, retrospective, and observational cohort study of adult OHT recipients. The primary outcome was major bleeding within the first month of starting anticoagulation. Secondary outcomes included clinically relevant non-major bleeding, major bleeding within the first three months and first year of anticoagulation therapy, incidence of CAV, and death.
Results:
Among the 126 patients included in the primary analysis, there were five and 19 major bleeding events in the AC group and AC+ASA group, respectively (p = 0.649). The AC group had 14.3 times higher odds of death than the AC+ASA group (OR 0.07, 95 % CI 0.01-0.32). There were no differences in other secondary outcomes.
Conclusion:
In our cohort, there was no evidence of a difference between groups for major bleeding within one month of anticoagulation initiation. Future research focusing on appropriateness of therapeutic anticoagulation in the acute period after transplant where patients are at an increased risk of bleeding may be beneficial.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:28Kidney Transplant I: Introduction
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:26Kidney Transplant II: Surgical Procedure